Teva Focus of FTC Investigation Over Inhaler Patents

Seeking AlphaJul 1 22:22

AI to Help Spur 15% Additional Gain in Tech Stocks in Second-half: Wedbush

Seeking AlphaJul 1 19:19

Teva Pharmaceuticals Presents 4th Interim Analysis Of PEARL Migraine Prevention Study At EAN Congress; New Sub-Analysis Highlights Potential Negative Impact Of Treatment Pauses On Patient Outcomes

4th interim analysis of PEARL real world migraine prevention study presented at 10th European Association of Neurology (EAN) congress in HelsinkiNew sub-analysis of PEARL data highlights potential neg

BenzingaJun 28 23:31

Jefferies Maintains Buy on Teva Pharmaceutical Indus, Raises Price Target to $23

Jefferies analyst Glen Santangelo maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Buy and raises the price target from $19 to $23.

BenzingaJun 27 23:37

Teva Pharmaceutical Indus Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 06/27/2024 39.56% Jefferies $19 → $23 Maintains Buy 06/05/2024 27.43% Barclays $20 → $21 Maintains Overwei

BenzingaJun 27 23:36

Amdocs Goes Ex Dividend Tomorrow

Seeking AlphaJun 27 22:37